Genentech, Inc.

Revolution Medicines, Inc.

F. Hoffmann-la Roche Ag

Mallika Singh

Lori Friedman

Deepak Sampath

Marcia Belvin

Jeffrey Wallin

Klaus Hoeflich

David E Wildes

Ulka Vijapurkar

Sonal Patel

Leisa Johnson

Elena S Koltun

Adrian L Gill

Naing N Aay

Yang Liu

James Joseph Cregg

John Edward Knox, Jr

Andreas Buckl

G Leslie Burnett

Maike Schmidt

Carlos Bais

W Clay Gustafson

Robert J Nichols

Bojena Bitman

Mark A Goldsmith

Matthew Brauer

Christopher Schulze

Jacqueline Smith

Stephen Kelsey

Ed Lorenzana

Bianca Jennifer Lee

Meghan A Rice

Yu Chi Yang

Zhengping Wang

Justin G Meyerowitz

Zhican Wang

The present disclosure relates to methods for the treatment of diseases or disorders (e.g., cancer) with mTOR inhibitors. Specifically, the disclosure relates to methods of treating a subject having a cancer by administering a particular dosage of an mTOR inhibitor. In some embodiments this disclosure includes methods for delaying, preventing, or treating acquired resistance to RAS inhibitors using a dosage of an mTOR inhibitor. In some embodiments, this disclosure relates to methods of treating or preventing adverse events associated with administration of an mTOR inhibitor using tacrolimus.

Methods of treating cancer with an mTOR inhibitor

The disclosure features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.

Ras inhibitors

The present invention is directed to compositions and methods of treating or preventing diseases or disorders with inhibitors of SHP2, alone, and in combination with other therapeutic agents such as RAS pathway inhibitors (e.g., MEK inhibitors); methods of establishing appropriate treatment plans for subjects based upon the expression of one or more biomarker indicative of SHP2 inhibitor sensitivity; and methods of determining sensitivity to a SHP2 inhibitor based on a phosphorylation status of SHP2.

SHP2 inhibitor compositions and methods for treating cancer

The invention provides methods and compositions to detect expression of one or more biomarkers for identifying and treating patients who are likely to be responsive to VEGF antagonist therapy. The invention also provides kits and articles of manufacture for use in the methods.

Biological markers for identifying patients for treatment with VEGF antagonists

Combinations of PI3K inhibitor compounds having Formulas I and II and chemotherapeutic agents, including stereoisomers, geometric isomers, tautomers, metabolites and pharmaceutically acceptable salts thereof, are useful for treating hyperproliferative disorders such as cancer. Methods of using such combinations for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed. 

Combinations of phosphoinositide 3-kinase inhibitor compounds chemotherapeutic agents, and methods of use

Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use

Growing community of inventors

San Francisco, CA, United States of America

Mallika Singh